ClinicalTrials.gg
Sign In
CompletedNCT00047658Updated Nov 6, 2007

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of Interferon-gamma 1b in Idiopathic Pulmonary Fibrosis, sponsored by InterMune. Completed at 1 site in United States. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2007-11-06.

Sponsored by InterMune (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Study summary

Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will be conducted at multiple sites and enroll 30 patients with IPF who have failed treatment with corticosteroids.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis
03

In context

Idiopathic Pulmonary Fibrosis

576 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 123 are open to participants now.

This study's enrollment of 32 is below the median of 55 across 389 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

InterMune is the lead sponsor of 15 studies on the registry; none are open to participants now.

First submitted before InterMune became part of Hoffmann-La Roche.

Browse InterMune studies →All Hoffmann-La Roche studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Male or Female 20-79 years old

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. change in percent predicted FVC, resting arterial blood gas assessment of alveolar-arterial oxygen gradient, percent predicted DLCO, dyspnea scale, baseline dyspnea index/transition dyspnea index

    Time frame: 23 weeks

07

Study locations

1 site
  • UCLA, Dept. of Medicine
    Los Angeles, California 90095, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001 and a completion of May 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2002
First posted
Oct 11, 2002
Start
Nov 2001
CompletionActual
May 2003
Last update
Nov 6, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00047658
Lead sponsor
InterMune
First posted
Oct 11, 2002
Start date
Nov 2001
Completion
May 2003
Last update
Nov 6, 2007

Study contacts

Williamson Bradford, MD
study director · InterMune
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon gamma-1b

Other studies in this condition

Idiopathic Pulmonary Fibrosis →

Other studies from this sponsor

InterMune →

Start the discussion